<div class="article-table-content" id="art40511-tbl-0002">
            <header class="article-table-caption"><span class="table-caption__label">Table 2.
            </span>SRI‐4 response rate and component scores at week 52<a class="noteLink scrollableLink" title="Link to note" id="art40511-note-0009_31-controller" href="#art40511-note-0009_31" aria-controls="art40511-note-0009_31" aria-haspopup="false" aria-expanded="true" aria-label="Link to Note">a</a><div class="footNotePopup" id="art40511-note-0009_31" aria-labelledby="art40511-note-0009_31-controller">
<button class="footNoteClose"><i class="icon-tools_close" aria-hidden="true"></i></button><span><span><sup><i>a</i></sup></span>
                     SRI‐4 = Systemic Lupus Erythematosus Responder 
Index 4; SC = subcutaneous; OR = odds ratio; 95% CI = 95% confidence 
interval; SELENA–SLEDAI = Safety of Estrogens in Lupus Erythematosus 
National Assessment version of the Systemic Lupus Erythematosus Disease 
Activity Index; PGA = physician's global assessment of disease activity;
 BILAG = British Isles Lupus Assessment Group.
                     <br></span><span class="chevronDown"></span>
</div>
            </header><div class="article-table-content-wrapper">
               <table class="table article-section__table">
<thead><tr>
<th class="bottom-bordered-cell right-bordered-cell left-aligned"></th>
                        
                        <th class="bottom-bordered-cell center-aligned">Placebo (n = 108)</th>
                        
                        <th class="bottom-bordered-cell center-aligned">SC belimumab 200 mg (n = 248)</th>
                        
                        <th class="bottom-bordered-cell center-aligned">OR (95% CI)</th>
                        
                        <th class="bottom-bordered-cell center-aligned">
                           <i>P</i>
                           
                        </th>
                        
                     </tr></thead>
<tbody>
<tr>
<td class="right-bordered-cell left-aligned">SRI‐4 response rate, %</td>
                        
                        <td class="center-aligned">47.2</td>
                        
                        <td class="center-aligned">64.6</td>
                        
                        <td class="center-aligned">2.23 (1.36, 3.64)</td>
                        
                        <td class="center-aligned">0.0014</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">4‐point reduction in SELENA–SLEDAI score, %</td>
                        
                        <td class="center-aligned">47.2</td>
                        
                        <td class="center-aligned">65.7</td>
                        
                        <td class="center-aligned">2.40 (1.46, 3.92)</td>
                        
                        <td class="center-aligned">0.0005</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">No worsening in PGA, %</td>
                        
                        <td class="center-aligned">68.5</td>
                        
                        <td class="center-aligned">82.5</td>
                        
                        <td class="center-aligned">2.16 (1.28, 3.65)</td>
                        
                        <td class="center-aligned">0.0040</td>
                        
                     </tr>
<tr>
<td class="right-bordered-cell left-aligned">No new A or and no more than 1 new BILAG B domain score, %</td>
                        
                        <td class="center-aligned">70.4</td>
                        
                        <td class="center-aligned">81.9</td>
                        
                        <td class="center-aligned">1.90 (1.12, 3.21)</td>
                        
                        <td class="center-aligned">0.0165</td>
                        
                     </tr>
</tbody>
</table>
</div>
            
            
            
            <div class="article-section__table-footnotes">
               <ul>
<li id="art40511-note-0009">
<span><sup><i>a</i></sup></span>
                     SRI‐4 = Systemic Lupus Erythematosus Responder 
Index 4; SC = subcutaneous; OR = odds ratio; 95% CI = 95% confidence 
interval; SELENA–SLEDAI = Safety of Estrogens in Lupus Erythematosus 
National Assessment version of the Systemic Lupus Erythematosus Disease 
Activity Index; PGA = physician's global assessment of disease activity;
 BILAG = British Isles Lupus Assessment Group.
                     
                  </li>
               </ul>
</div>
            <div class="article-section__table-source"></div>
         </div>